Taiho ( Taiho )

Taiho

Taiho's picture

Taiho Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo, Japan. Taiho is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology. Taiho is the Japanese second-largest by prescription oral oncology sales.

Taiho press release, blog etc

10/19/2017 - 22:27 Health Canada Grants Priority Review Status to TAS-102 (brand name in Japan: "LONSURF ") for Refractory Metastatic Colorectal Cancer
10/04/2017 - 20:33 Taiho Pharmaceutical Releases Pitas Sore Throat Troche in Japan on October 5
10/03/2017 - 18:22 Taiho Pharmaceutical to Participate in Japan Healthcare Venture Summit 2017
09/06/2017 - 19:50 Taiho Pharmaceutical releases Harncare Granules nationwide in Japan on Thursday, September 7an effective herbal remedy to improve urinary function by warming up the body from the inside.
08/25/2017 - 01:47 Antitumor Agent Abraxane I.V. Infusion 100 mg Approved for Additional Dosage and Administration for Gastric Cancer
05/18/2017 - 00:38 Taiho Pharmaceutical Receives Approval for the Additional Indications of Complicated Skin and Soft Tissue Infections for ZOSYN
03/07/2017 - 11:44 Taiho Pharmaceutical Announces Expansion into Canada
02/07/2017 - 14:01 Taiho Pharmaceutical Releases Pure Quick S Ointment, a New Mini Size Steroid Product
02/06/2017 - 01:09 Taiho Pharmaceutical Receives Platinum Kurumin Certification as a Good Supporter of Child-rearing
09/27/2016 - 23:06 Taiho Pharmaceutical Receives Approval to Manufacture and Market Bilanoa Tablets, an Oral Anti-allergy Drug in Japan
07/28/2016 - 23:28 Application for Additional Indications of Complicated Skin and Soft Tissue Infections (Including Diabetic Foot Infections) for ZOSYN
05/10/2016 - 04:48 Taiho Pharmaceutical Forms Taiho Ventures to Foster Oncology Biotech Start-ups
04/11/2016 - 02:27 Tiovita series to go on sale outside Japan Tiovita 3000 to Be Released in Hong Kong Supporting the hard workers of Hong Kong
04/01/2016 - 00:44 Taihos TAS-102 Meets Primary Endpoint of Improving Overall Survival in Phase III TERRA Study in Asian Patients with Refractory Metastatic Colorectal Cancer
02/25/2016 - 21:52 Patients with Advanced Metastatic Colorectal Cancer in Europe Now Have New Treatment Option as LONSURF (trifluridine/tipiracil) Receives EU Approval
11/26/2015 - 12:31 NHI Reimbursement Price Listing and Launch of the Novel Antitumor Agent “Yondelis® IV Infusion”
11/13/2015 - 07:11 Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market TAC-202 (bilastine), an Oral Anti-allergy Drug in Japan
09/28/2015 - 00:00 Novel Antitumor Agent “Yondelis® IV Infusion” Approved in Japan for Treatment of Soft Tissue Sarcoma